Chugai Pharmaceutical (OTCMKTS:CHGCY) Sees Large Volume Increase – Time to Buy?

Chugai Pharmaceutical Co., Ltd. Unsponsored ADR (OTCMKTS:CHGCY) shares saw unusually-high trading volume on Friday . 117,193 shares were traded during trading, a decline of 52% from the previous session’s volume of 241,954 shares.The stock last traded at $22.3835 and had previously closed at $22.11.

Analyst Upgrades and Downgrades

A number of brokerages have recently commented on CHGCY. The Goldman Sachs Group raised shares of Chugai Pharmaceutical from a “hold” rating to a “buy” rating in a research note on Monday, June 15th. Zacks Research raised shares of Chugai Pharmaceutical to a “hold” rating in a report on Friday, May 29th. Two investment analysts have rated the stock with a Strong Buy rating, one has issued a Buy rating and one has issued a Hold rating to the stock. According to data from MarketBeat.com, the company has an average rating of “Buy”.

Chugai Pharmaceutical Price Performance

The stock has a 50 day moving average price of $23.46 and a 200-day moving average price of $26.43. The stock has a market capitalization of $72.67 billion, a price-to-earnings ratio of 24.53 and a beta of 0.59.

Chugai Pharmaceutical (OTCMKTS:CHGCY) last issued its earnings results on Friday, July 24th. The company reported $0.22 EPS for the quarter. Chugai Pharmaceutical had a net margin of 34.98% and a return on equity of 22.90%. As a group, research analysts forecast that Chugai Pharmaceutical Co., Ltd. Unsponsored ADR will post 0.98 earnings per share for the current year.

Chugai Pharmaceutical Company Profile

Chugai Pharmaceutical Co, Ltd. is a Japan-based biopharmaceutical company headquartered in Tokyo that focuses on the discovery, development, manufacture and marketing of prescription medicines. The company develops both biologics and small-molecule therapies, with particular emphasis on oncology and immunology as well as treatments for bone and metabolic disorders. Chugai’s activities span the full drug lifecycle from early research and clinical development through regulatory approval, manufacturing and post-marketing support.

Chugai is known for its research-driven approach and its work on monoclonal antibodies and other biologic therapeutics.